Physician profile
Mohammad Kamran
NPI 1811194681
$32,652.34
in general payments reported to CMS, 2019-2025
26 companies · $5,558 in 2025
The $5,558 reported for 2025 was more than what 87% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,303 · 2020: $567 · 2021: $5,379 · 2022: $12K · 2023: $5,824 · 2024: $1,221 · 2025: $5,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Consulting Fee: $4,108 · Food and Beverage: $3,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Consulting Fee | $4,107.50 |
| Food and Beverage | $3,996.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $20,087.42 | 2021-2024 | Lupkynis |
| Sobi, INC | $4,256.37 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,091.51 | 2019-2025 | Benlysta, Nucala |
| Abbvie INC. | $1,977.40 | 2019-2025 | |
| Amgen INC. | $1,066.75 | 2020-2025 | Tavneos, Evenity, Enbrel |
| Novartis Pharmaceuticals Corporation | $604.03 | 2020-2025 | |
| Ucb, INC. | $486.24 | 2022-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $446.83 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals Lp | $288.00 | 2021-2025 | Saphnelo |
| Janssen Biotech, INC. | $212.95 | 2019-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.39 | 2021-2024 | Ofev, Cyltezo |
| Horizon Therapeutics Plc | $129.59 | 2020-2022 | |
| Pfizer INC. | $122.53 | 2019-2024 | |
| Genzyme Corporation | $104.95 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $83.05 | 2023-2024 | Acthar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $81.45 | 2019-2023 | Euflexxa |
| Octapharma USA, INC. | $75.38 | 2023-2024 | Octagam Immune Globulin (Human), Panzyga |
| Radius Health, INC. | $74.63 | 2019-2024 | Tymlos |
| Lilly USA, LLC | $65.75 | 2019-2021 | |
| Genentech USA, INC. | $59.67 | 2019-2022 | |
| Medexus Pharma, INC. | $52.32 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $26.96 | 2024 | Sovuna |
| Sandoz INC. | $19.57 | 2023 | Hyrimoz |
| United Therapeutics Corporation | $19.37 | 2020 | |
| Alexion Pharmaceuticals, INC. | $19.16 | 2025 | Strensiq |
| Celgene Corporation | $17.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Kamran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.